CytRx Corp (CYTR) - Financial and Strategic SWOT Analysis Review

Date: June 22, 2017
Pages: 48
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C49085EBA50EN
Leaflet:

Download PDF Leaflet

CytRx Corp (CYTR) - Financial and Strategic SWOT Analysis Review
CytRx Corp (CYTR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

CytRx Corp (CytRx) is a clinical state is a biopharmaceutical company focusing on the research and development of novel treatments for cancer. The company’s oncology based product mainly comprises its lead drug product candidate, aldoxorubicin (formerly INNO-206). Aldoxorubicin is a pro-drug of the commonly prescribed chemotherapeutic doxorubicin, designed to reduce adverse events by controlling release and preferentially targeting the tumor. Its other new albumin-binding drug conjugates are under pre-clinical development. The company conducts its discovery and translational research at its discovery laboratory located in Freiburg, Germany. It has a strategic alliance with KTB Tumorforschungs GmbH. CytRx is headquartered in Los Angeles, California, the US.

CytRx Corp Key Recent Developments

Jun 13,2017: CytRx Announces Reshaping of Clinical and Regulatory Executive Team
May 10,2017: CytRx Reports First Quarter 2017 Financial Results
Mar 15,2017: CytRx Reports 2016 Financial Results
Dec 02,2016: CytRx appoints new board member
Nov 09,2016: CytRx Reports Third Quarter 2016 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

CytRx Corp - Key Facts
CytRx Corp - Key Employees
CytRx Corp - Key Employee Biographies
CytRx Corp - Major Products and Services
CytRx Corp - History
CytRx Corp - Company Statement
CytRx Corp - Locations And Subsidiaries
Head Office

SECTION 2 – COMPANY ANALYSIS

CytRx Corp - Business Description
CytRx Corp - SWOT Analysis
SWOT Analysis - Overview
CytRx Corp - Strengths
CytRx Corp - Weaknesses
CytRx Corp - Opportunities
CytRx Corp - Threats
CytRx Corp - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

CytRx Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
CytRx Corp, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
CytRx Corp, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jun 13, 2017: CytRx Announces Reshaping of Clinical and Regulatory Executive Team
May 10, 2017: CytRx Reports First Quarter 2017 Financial Results
Mar 15, 2017: CytRx Reports 2016 Financial Results
Dec 02, 2016: CytRx appoints new board member
Nov 09, 2016: CytRx Reports Third Quarter 2016 Financial Results
Jul 29, 2016: CytRx Reports Second Quarter 2016 Financial Results
May 11, 2016: CytRx Reports First Quarter 2016 Financial Results
Mar 11, 2016: CytRx Reports 2015 Financial Results
Jan 11, 2016: CytRx Appoints Olivia Ware as Chief Commercial Officer

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

CytRx Corp, Key Facts
CytRx Corp, Key Employees
CytRx Corp, Key Employee Biographies
CytRx Corp, Major Products and Services
CytRx Corp, History
CytRx Corp, Key Competitors
CytRx Corp, Ratios based on current share price
CytRx Corp, Annual Ratios
CytRx Corp, Annual Ratios (Cont...1)
CytRx Corp, Interim Ratios
CytRx Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
CytRx Corp, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
CytRx Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

CytRx Corp, Performance Chart (2012 - 2016)
CytRx Corp, Ratio Charts
CytRx Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
CytRx Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

ZIOPHARM Oncology Inc
Sanofi
Pharmacyclics Inc
Johnson & Johnson
GlaxoSmithKline LLC
FirstString Research Inc
CTI BioPharma Corp
AstraZeneca Plc
Skip to top


Ask Your Question

CytRx Corp (CYTR) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: